Kamel Abou Hussein, MD

Articles by Kamel Abou Hussein, MD

Treatment Sequencing in Later Lines of Therapy in HER2+ Metastatic Breast Cancer

ByNeil M. Iyengar, MD,Kelly E. McCann, MD, PhD,Kamel Abou Hussein, MD,William J. Gradishar, MD,Sara A. Hurvitz, MD, FACP

November 18th 2025

Panelists discuss how thoughtful sequencing of HER2-targeted agents maximizes benefit and extends survival in metastatic settings.

Benjamin P. Levy, MD Kamel Abou Hussein, MD Victoria Rizk, MD

Advances in Breast Cancer ADCs and Endocrine Therapy Take Center Stage at CFS: With Benjamin P. Levy, MD; Kamel Abou Hussein, MD; and Victoria Rizk, MD

ByBenjamin P. Levy, MD,Victoria Rizk, MD,Kamel Abou Hussein, MD

November 17th 2025

Benjamin P. Levy, MD leads a live CFS discussion with Kamel Abou Hussein, MD and Victoria Rizk, MD on the evolving therapeutic landscape in breast cancer.

First-Line Treatment Regimens in Metastatic HER2+ Breast Cancer

ByNeil M. Iyengar, MD,Kelly E. McCann, MD, PhD,Kamel Abou Hussein, MD,William J. Gradishar, MD,Sara A. Hurvitz, MD, FACP

November 11th 2025

Panelists discuss how evolving first-line HER2-targeted combinations are improving outcomes and redefining standards in metastatic breast cancer..

The Role of ADCs in Different Subgroups

ByNeil M. Iyengar, MD,Kelly E. McCann, MD, PhD,Kamel Abou Hussein, MD,William J. Gradishar, MD,Sara A. Hurvitz, MD, FACP

November 11th 2025

Panelists discuss how ADCs are revolutionizing HER2-targeted therapy through precision delivery and improved tolerability across patient subgroups.

Clinical Trial Evidence for HER2-Targeted Therapies in Early Breast Cancer

ByNeil M. Iyengar, MD,Kelly E. McCann, MD, PhD,Kamel Abou Hussein, MD,William J. Gradishar, MD,Sara A. Hurvitz, MD, FACP

November 3rd 2025

Panelists discuss how new trial data are optimizing early-stage HER2-positive breast cancer treatment through refined, evidence-based regimens.

Background Information on Targeted Therapies in Breast Cancer

ByNeil M. Iyengar, MD,Kelly E. McCann, MD, PhD,Kamel Abou Hussein, MD,William J. Gradishar, MD,Sara A. Hurvitz, MD, FACP

November 3rd 2025

Panelists discuss how the evolution of HER2 testing and classification has redefined treatment strategies and expanded therapeutic opportunities in breast cancer.

Kamel Abou Hussein, MD

Articles by Kamel Abou Hussein, MD

Treatment Sequencing in Later Lines of Therapy in HER2+ Metastatic Breast Cancer

Advances in Breast Cancer ADCs and Endocrine Therapy Take Center Stage at CFS: With Benjamin P. Levy, MD; Kamel Abou Hussein, MD; and Victoria Rizk, MD

First-Line Treatment Regimens in Metastatic HER2+ Breast Cancer

The Role of ADCs in Different Subgroups

Clinical Trial Evidence for HER2-Targeted Therapies in Early Breast Cancer

Background Information on Targeted Therapies in Breast Cancer

Trending on OncLive

Dr Wander on the Evolving First-Line and Post–T-DXd Landscape in HER2+ Metastatic Breast Cancer

Combination Therapy Overcomes Treatment Resistance in Breast Cancer Models

Dr Levy on Where Iza-Bren May Fit Following Osimertinib In EGFR-Mutated NSCLC

Dr Levy on How the EGFR-Targeted Therapy Landscape Has Evolved in NSCLC

Detalimogene Responses Improve With Longer Follow-Up in BCG-Unresponsive NMIBC Ahead of BLA Submission